Effects of CETP inhibition on triglyceride-rich lipoprotein composition and apoB-48 metabolism

Journal of Lipid Research

Volumn 53, Issue 6, 2012, Pages 1190-1199

  Diffenderfer, Margaret R ^a   Brousseau, Margaret E ^a   Millar, John S ^c   Barrett, P Hugh R ^d   Nartsupha, Chorthip ^a   Schaefer, Peter M ^a   Wolfe, Megan L ^c   Dolnikowski, Gregory G ^b   Rader, Daniel J ^c   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Apolipoprotein; Cholesteryl ester transfer protein; Lipoprotein kinetics; Postprandial metabolism; Torcetrapib

Indexed keywords

APOLIPOPROTEIN B48; ATORVASTATIN; CHOLESTEROL ESTER; LEUCINE; LIPOPROTEIN; PLACEBO; TORCETRAPIB; TRIGLYCERIDE RICH LIPOPROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; LIPID COMPOSITION; LIPOPROTEIN METABOLISM; LIPOPROTEIN SYNTHESIS; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN SYNTHESIS REGULATION; SINGLE BLIND PROCEDURE; TREATMENT DURATION;

EID: 84861450585     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M019570     Document Type: Article

References (46)

1. Zilversmit, D. B. 1995. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich-remnant lipoproteins. Clin. Chem. 41: 153-158.
2. Karpe, F. 1999. Postprandial lipoprotein metabolism and atherosclerosis. J. Intern. Med. 246: 341-355. (Pubitemid 29479916)
3. Patsch, J. R., G. Miesenböck, T. Hopferwieser, V. Mühlberger, E. Knapp, J. K. Dunn, A. M. Gotto, Jr., and W. Patsch. 1992. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. Arterioscler. Thromb. 12: 1336-1345.
4. Proctor, S. D., D. F. Vine, and J. C. L. Mamo. 2002. Arterial retention of apolipoprotein B 48-and B 100 -containing lipoproteins in atherogenesis. Curr. Opin. Lipidol. 13: 461-470. (Pubitemid 35231925)
5. Otokozawa, S., M. Ai, T. Van Himbergen, M. R. Diffenderfer, B. F. Asztalos, A. Tanaka, S. Lamon-Fava, and E. J. Schaefer. 2009. Fasting and postprandial apolipoprotein B-48 levels in healthy, obese, and hyperlipidemic subjects. Metabolism. 58: 1536-1542.
6. Young, S. G. 1990. Recent progress in understanding apolipoprotein B. Circulation. 82: 1574-1594. (Pubitemid 20367961)
7. Hussain, M. M. 2000. A proposed model for the assembly of chylomicrons. Atherosclerosis. 148: 1-15.
8. Davidson, N. O., and G. S. Shelness. 2000. Apolipoprotein B: mRNA edition, lipoprotein assembly, and presecretory degradation. Annu. Rev. Nutr. 20: 169-193.
9. Silva, K. D. R. R., C. N. M. Kelly, A. E. Jones, R. D. Smith, S. A. Wootton, G. J. Miller, and C. M. Williams. 2003. Chylomicron particle size and number, factor VII activation and dietary monounsaturated fatty acids. Atherosclerosis. 166: 73-84. (Pubitemid 35449603)
10. Mahley, R. W., and S. C. Rall, Jr. 2000. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1: 507-537.
11. Kowal, R. C., J. Herz, J. L. Goldstein, V. Esser, and M. S. Brown. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86: 5810-5814. (Pubitemid 19217543)
12. Guerin, M., P. Egger, C. Soudant, W. Le Goff, A. van Tol, R. Dupuis, and M. J. Chapman. 2002. Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the postprandial state. J. Lipid Res. 43: 1652-1660. (Pubitemid 35168279)
13. Schaefer, E. J., R. I. Levy, D. W. Anderson, R. N. Danner, H. B. Brewer, Jr., and W. C. Blackwelder. 1978. Plasma-triglycerides in regulation of H.D.L.-cholesterol levels. Lancet. 312: 391-393.
14. Lamarche, B., K. D. Uffelman, A. Carpentier, J. S. Cohn, G. Steiner, P. H. Barrett, and G. F. Lewis. 1999. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apoA-I in healthy men. J. Clin. Invest. 103: 1191-1199. (Pubitemid 29207253)
15. Brousseau, M. E., E. J. Schaefer, M. L. Wolfe, L. T. Bloedeon, A. G. Digenio, R. W. Clark, J. P. Mancuso, and D. J. Rader. 2004. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N. Engl. J. Med. 350: 1505-1515. (Pubitemid 38477775)
16. Brousseau, M. E., M. R. Diffenderfer, J. S. Millar, C. Nartsupha, B. F. Asztalos, F. K. Welty, M. L. Wolfe, M. Rudling, I. Björkhem, B. Angelin, et al. 2005. Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion. Arterioscler. Thromb. Vasc. Biol. 25: 1057-1064. (Pubitemid 40627855)
17. Millar, J. S., M. E. Brousseau, M. R. Diffenderfer, P. H. R. Barrett, F. K. Welty, A. Faruqi, M. L. Wolfe, C. Nartsupha, A. G. Digenio, J. P. Mancuso, et al. 2006. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on apolipoprotein B100 metabolism in humans. Arterioscler. Thromb. Vasc. Biol. 26: 1350-1356. (Pubitemid 44305381)
18. Millar, J. S., M. E. Brousseau, M. R. Diffenderfer, P. H. R. Barrett, F. K. Welty, J. S. Cohn, A. Wilson, M. L. Wolfe, C. Nartsupha, P. M. Schaefer, et al. 2008. Effects of the cholesteryl ester transfer protein inhibitor torcetrapib on VLDL apolipoprotein E metabolism. J. Lipid Res. 49: 543-549.
19. Cohn, J. S., D. A. Wagner, S. D. Cohn, J. S. Millar, and E. J. Schaefer. 1990. Measurement of very low density and low density lipoprotein apolipoprotein (apo) B-100 and high density lipoprotein apoA-I production in human subjects using deuterated leucine. Effect of fasting and feeding. J. Clin. Invest. 85: 804-811. (Pubitemid 20087484)
20. Lichtenstein, A. H., D. L. Hachey, J. S. Millar, J. L. Jenner, L. Booth, J. Ordovas, and E. J. Schaefer. 1992. Measurement of human apolipoprotein B-48 and B-100 kinetics in triglyceride-rich lipoproteins using [5,5,5- 2 H 3 ]leucine. J. Lipid Res. 33: 907-914.
21. Havel, R. J., H. Eder, and J. Bragdon. 1955. The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. J. Clin. Invest. 34: 1345-1353.
22. Lamon-Fava, S., M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, N. R. Matthan, A. H. Lichtenstein, G. G. Dolnikowski, K. Horvath, B. F. Asztalos, V. Zago, et al. 2007. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res. 48: 1746-1753. (Pubitemid 47311991)
23. Cobelli, C., G. Toffolo, D. Bier, and R. Nosadini. 1987. Models to interpret kinetic data in stable isotope tracer studies. Am. J. Physiol. 253: E551-E564.
24. Welty, F. K., A. H. Lichtenstein, P. H. R. Barrett, G. G. Dolnikowski, and E. J. Schaefer. 1999. Human apolipoprotein (apo) B-48 and apoB-100 kinetics with stable isotopes. Arterioscler. Thromb. Vasc. Biol. 19: 2966-2974.
25. Lamon-Fava, S., M. R. Diffenderfer, P. H. R. Barrett, A. Buchsbaum, M. Nyaku, K. V. Horvath, B. F. Asztalos, S. Otokozawa, M. Ai, N. R. Matthan, et al. 2008. Extended-release niacin alters the metabolism of plasma apolipoprotein (apo) A-I and apoB-containing lipoproteins. Arterioscler. Thromb. Vasc. Biol. 28: 1672-1678.
26. McNamara, J. R., and E. J. Schaefer. 1987. Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin. Chim. Acta. 166: 1-8. (Pubitemid 17095867)
27. Zilversmit, D. B., and T. M. Shea. 1989. Quantitation of apoB-48 and apoB-100 by gel scanning or radio-iodination. J. Lipid Res. 30: 1639-1646. (Pubitemid 19271059)
28. Barter, P. J., M. Caulfield, M. Eriksson, S. M. Grundy, J. J. P. Kastelein, M. Komajda, J. Lopez-Sendon, L. Mosca, J-C. Tardif, D. D. Waters, C. L. Shear, J. H. Revkin, K. A. Buhr, M. R. Fisher, A. R. Tall, and B. Brewer for the ILLUMINATE Investigators. 2007. Effects of torcetrapib in patients at high risk for coronary events. N. Engl. J. Med. 357: 2109-2122. (Pubitemid 350146106)
29. Nicholls, S. J., E. M. Tuzcu, D. M. Brennan, J-C. Tardif, and S. E. Nissen. 2008. Cholesteryl ester transfer protein inhibition, highdensity lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 118: 2506-2514.
30. Forrest, M. J., D. Bloomfield, R. J. Briscoe, P. N. Brown, A-M. Cumiskey, J. Ehrhart, J. C. Hershey, W. J. Keller, X. Ma, H. E. McPherson, et al. 2008. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br. J. Pharmacol. 154: 1465-1473.
31. Krishna, R., M. S. Anderson, A. J. Bergman, B. Jin, M. Fallon, J. Cote, K. Rosko, C. Chavez-Eng, R. Lutz, D. M. Bloomfield, et al. 2007. Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomized placebo-controlled phase I studies. Lancet. 370: 1907-1914. (Pubitemid 350192656)
32. Stein, E. A., E. S. G. Stroes, G. Steiner, B. M. Buckley, A. M. Capponi, T. Burgess, E. J. Niesor, D. Kallend, and J. J. P. Kastelein. 2009. Safety and tolerability of dalcetrapib. Am. J. Cardiol. 104: 82-91.
33. Cohn, J. S., E. J. Johnson, J. S. Millar, S. D. Cohn, R. W. Milne, Y. L. Marcel, R. M. Russell, and E. J. Schaefer. 1993. Contribution of apoB-48 and apoB-100 triglyceride-rich lipoproteins (TRL) to postprandial increase in the plasma concentration of TRL triglycerides and retinyl esters. J. Lipid Res. 34: 2033-2040. (Pubitemid 24000952)
34. Niesor, E. J., E. Chaput, A. Staempfli, D. Blum, M. Derks, and D. Kallend. 2011. Effect of dalcetrapib, a CETP modulator, on noncholesterol sterol markers of cholesterol homeostasis in healthy subjects. Atherosclerosis. 219: 761-767.
35. Trevaskis, N. L., R. M. Shanker, W. N. Charman, and C. H. J. Porter. 2010. The mechanism of lymphatic access of two cholesteryl ester transfer protein inhibitors (CP524,515 and CP532,623) and evaluation of their impact on lymph lipoprotein profiles. Pharm. Res. 27: 1949-1964.
36. Parhofer, K. G., E. Laubach, and P. H. R. Barrett. 2003. Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J. Lipid Res. 44: 1192-1198. (Pubitemid 37279637)
37. Otokozawa, S., M. Ai, T. Van Himbergen, B. F. Asztalos, A. Tanaka, E. A. Stein, P. H. Jones, and E. J. Schaefer. 2009. Effects of intensive atorvastatin and rosuvastatin treatment on apolipoprotein B-48 and remnant lipoprotein cholesterol levels. Atherosclerosis. 205: 197-201.
38. Ishigami, M., S. Yamashita, N. Sakai, K. Hirano, H. Hiraoka, T. Nakamura, and Y. Matsuzawa. 2003. Atorvastatin markedly improves type III hyperlipoproteinemia in association with reduction of both exogenous and endogenous apolipoprotein B-containing lipoproteins. Atherosclerosis. 168: 359-366. (Pubitemid 36705541)
39. Guerin, M., P. Egger, W. Le Goff, C. Soudant, R. Dupuis, and M. J. Chapman. 2002. Atorvastatin reduces postprandial accumulation and cholesteryl ester transfer protein-mediated remodeling of triglyceride-rich lipoprotein subspecies in type IIB hyperlipidemia. J. Clin. Endocrinol. Metab. 87: 4991-5000. (Pubitemid 35316337)
40. Dane-Stewart, C. A., G. F. Watts, S. Pal, D. Chan, P. Thompson, J. Hung, and J. C. L. Mamo. 2003. Effect of atorvastatin on apolipoprotein B 48 metabolism and low-density lipoprotein receptor activity in normolipidemic patients with coronary artery disease. Metabolism. 52: 1279-1286. (Pubitemid 37351095)
41. Schaefer, E. J., J. R. McNamara, T. Tayler, J. A. Daly, J. A. Gleason, L. J. Seman, A. Ferrari, and J. J. Rubenstein. 2002. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am. J. Cardiol. 90: 689-696. (Pubitemid 35279386)
42. Sposito, A. C., R. D. Santos, R. F. Amâncio, J. A. F. Ramiers, M. J. Chapman, and R. C. Maranhão. 2003. Atorvastatin enhances the plasma clearance of chylomicron-like emulsions in subjects with atherogenic dyslipidemia: relevance to the in vivo metabolism of triglyceride-rich lipoproteins. Atherosclerosis. 166: 311-321. (Pubitemid 36074974)
43. Hogue, J-C., B. Lamarche, Y. Deshaies, A. J. Tremblay, J. Bergeron, C. Gagné, and P. Couture. 2008. Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia. Metabolism. 57: 246-254.
44. Tremblay, A. J., B. Lamarche, V. Lemelin, L. Hoos, S. Benjannet, N. G. Seidah, H. R. Davis, Jr., and P. Couture. 2011. Atorvastatin increases intestinal expression of NPC1L1 in hyperlipidemic men. J. Lipid Res. 52: 558-565.
45. Guerin, M., W. Le Goff, E. Duchene, Z. Julia, T. Nguyen, T. Thuren, C. L. Shear, and M. J. Chapman. 2008. Inhibition of CETP by torcetrapib attenuates the atherogenicity of postprandial TG-rich lipoproteins in type IIB hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 28: 148-154.
46. Schaefer, E. J., R. E. Gregg, G. Ghiselli, T. M. Forte, J. M. Ordovas, L. A. Zech, and H. B. Brewer, Jr. 1986. Familial apolipoprotein E deficiency. J. Clin. Invest. 78: 1206-1219. (Pubitemid 17181558)